Bayer has filed its mineralocorticoid receptor antagonist (MRA) finerenone as a treatment for a common form of heart failure ...

Inspra (eplerenone tablets; Pfizer, Inc., New York, NY) is an aldosterone blocker that works by binding at the mineralocorticoid receptor. It has some similarities to the potassium-sparing ...

Nephrologists jumped on the GLP-1 bandwagon well before Novo Nordisk won FDA approval for Ozempic in chronic kidney disease ...

Finerenone treatment vs placebo was associated with a reduced risk for new-onset diabetes by 24% among patients with HFmrEF or HFpEF.

Bayer seeks European marketing approval for use of finerenone in adult patients with HF with a left ventricular ejection fraction (LVEF) of =40%: Berlin Tuesday, February 4, 2025, ...

Berlin: Bayer has announced the submission of a marketing authorization application to the European Medicines Agency (EMA), ...

Cardiac and renal protection by a new mineralocorticoid receptor antagonist in salt-sensitive hypertension [abstract P754]. Eur. Heart J. 27 (Suppl. 1), 110 (2006).

Use of finerenone for heart failure with preserved ejection fraction carries a hyperkalemia risk, especially in patients with kidney disease.

The addition of β-adrenergic antagonists to the treatment regimen for heart failure has validated the neurohormonal hypothesis and provided much-improved outcomes. This benefit had been in ...

Finerenone is the first drug targeting the mineralocorticoid receptor (MR) pathway to demonstrate cardiovascular benefits in a Phase III study in patients ...